A long‐established approach to the pharmacological treatment of disease has been to start low and go slow. However, clinicians often prescribe up to maximum tolerated dose (MTD), especially when treating acute and more severe disease, without evidence to show that MTD is more likely to improve outcomes. Cardiovascular guidelines for some indications advocate MTD even in prevention, for example hypercholesterolaemia, without compelling evidence of better outcomes. This review explores the origins and potential problems of prescribing medications at MTD. Oral effective dose 50 (ED50) may be a useful guide for balancing efficacy and safety.
History
Journal title
British Journal of Clinical Pharmacology
Volume
85
Issue
10
Pagination
2213-2217
Publisher
Wiley-Blackwell
Language
en, English
College/Research Centre
Faculty of Health and Medicine
School
School of Medicine and Public Health
Rights statement
This is the peer reviewed version of above article, which has been published in final form at https://doi.org/10.1111/bcp.14032. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.